Bristol Myers Squibb reports interim Phase 1 data for CAR T-cell therapy zola-cel in multiple sclerosis

Bristol Myers Squibb presented interim Phase 1 Breakfree-2 study results for zolacabtagene autoleucel (zola-cel) in multiple sclerosis at MS Toronto 2026. All 60 patients at the second dose level remained off disease-modifying therapies, 92% of evaluable progressive MS patients showed stable or improved disability, and none showed new MRI activity. Safety data showed cytokine release syndrome in 42.4% of patients and neurotoxicity in 7.6%.

Detected & updated continuously · Source: Nebula